■限制的平均生存时间是预期的生存持续时间,直到选定的限制时间τ。对于比较研究,两组之间的有限平均生存时间的差异提供了治疗效果的汇总度量,没有关于两条生存曲线的相对形状的假设。比如比例风险。然而,由于在时间τ处的观察结果被截断,因此很难从受限均值的比较中判断效果的大小。
■在本文中,我们描述了基于限制手段的其他表达治疗效果的方法,这些方法在这方面可能是有帮助的。这些包括限制手段的比率,损失的寿命年(或时间)之比,和存活曲线之间的平均积分差异,等于限制均值之差除以τ。这些替代度量易于计算,并提供了一种用于缩放效果大小的方法,以帮助解释。来自两个随机的例子,前列腺癌的多中心临床试验,NRG/RTOG0521和NRG/RTOG0534,主要终点为总生存期和生化/放射学无进展生存期,分别,是为了说明这些想法而提出的。
■四种效应测量(受限平均生存时间差,受限平均生存时间比率,时间损失率,和平均生存率差异)为0.45年,RTOG0521和1.36年的1.05、0.81和0.038,τ=12年和11年的RTOG0534为1.17、0.56和0.12,分别。因此,例如,第一次试验的0.45年差异转化为19%的时间损失和3.8%的平均绝对差异之间的存活曲线在12年的范围内,适度的效应大小,而第二项试验的1.36年差异相当于减少44%的时间损失和12%的绝对生存差异,相当大的影响。
■除了限制平均生存时间的差异外,这些替代措施有助于确定治疗效果的大小是否具有临床意义.
UNASSIGNED: Restricted mean survival time is the expected duration of survival up to a chosen time of restriction τ. For comparison studies, the difference in restricted mean survival times between two groups provides a summary measure of the treatment effect that is free of assumptions regarding the relative shape of the two survival curves, such as proportional hazards. However, it can be difficult to judge the magnitude of the effect from a comparison of restricted means due to the truncation of observation at time τ.
UNASSIGNED: In this article, we describe additional ways of expressing the treatment effect based on restricted means that can be helpful in this regard. These include the ratio of restricted means, the ratio of life-years (or time) lost, and the average integrated difference between the survival curves, equal to the difference in restricted means divided by τ. These alternative metrics are straightforward to calculate and provide a means for scaling the effect size as an aid to interpretation. Examples from two randomized, multicenter clinical trials in prostate cancer, NRG/RTOG 0521 and NRG/RTOG 0534, with primary endpoints of overall survival and biochemical/radiological progression-free survival, respectively, are presented to illustrate the ideas.
UNASSIGNED: The four effect measures (restricted mean survival time difference, restricted mean survival time ratio, time lost ratio, and average survival rate difference) were 0.45 years, 1.05, 0.81, and 0.038 for RTOG 0521 and 1.36 years, 1.17, 0.56, and 0.12 for RTOG 0534 with τ = 12 and 11 years, respectively. Thus, for example, the 0.45-year difference in the first trial translates into a 19% reduction in time lost and a 3.8% average absolute difference between the survival curves over the 12-year horizon, a modest effect size, whereas the 1.36-year difference in the second trial corresponds to a 44% reduction in time lost and a 12% absolute survival difference, a rather large effect.
UNASSIGNED: In addition to the difference in restricted mean survival times, these alternative measures can be helpful in determining whether the magnitude of the treatment effect is clinically meaningful.